Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02494167 · ClinicalTrials.gov registry record · Phase 1

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Baylor College of Medicine.

Active
Registry status
Phase 1
Development phase
44
Enrollment target
2
Study locations

NCT02494167: Active Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by Baylor College of Medicine.

NCT02494167 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 44 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02494167, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by Baylor College of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
44 participants
Enrollment target
2
Study locations

Study Summary

This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) which has come back, or may come back, or has not gone away after standard treatment, including an allogeneic hematopoietic stem cell transplant (HSCT). The investigators have previously used this sort of therapy to treat Hodgkin or non-Hodgkin lymphomas that are infected with Epstein-Barr virus (EBV). EBV is found in cancer cells of up to half of all patients with Hodgkin and non-Hodgkin lymphoma. This suggests that it may play a role in causing lymphoma. The cancer cells infected by EBV are able to hide from the body's immune system and escape being killed. The investigators previously tested whether special white blood cells (called T cells) that were trained to kill EBV-infected cells could affect these tumors, and in many patients the investigators found that giving these trained T cells causes a complete or partial response. Other cancers express specific proteins that can be targeted in the same way. The investigators have been able to infuse such tumor-targeted cells into up to 10 patients with lymphoma who do not have EBV, and seen some complete responses. Importantly, the treatment appears to be safe. Therefore, the investigators now want to test whether the investigators can direct these special T cells against other types of cancers that carry similar proteins called tumor-associated antigens (TAAs). These proteins are specific to the cancer cell, so they either do not show up, or show up in low quantities, or normal human cells. The investigators will grow T cells from patients' stem cell donors in the laboratory in a way that will train them to recognize the tumor proteins WT1, NY-ESO-1, PRAME, and Survivin, which are expressed on most AML and MDS cancer cells. The cells will be infused at least 30 days post-allogeneic stem cell

Primary Outcome

Maximum tolerated dose (MTD) of multiTAA-specific T cells among the five pre-specified dose levels.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome

Interventions

  • BIOLOGICAL MultiTAA-specific T cells

Study Locations (2)

Texas

  • Houston Methodist Hospital - Houston
  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2016-02
Est. Completion 2027-02
Phase Phase 1
Baylor College of Medicine

616 total trials

What the registry record for NCT02494167 still lists

NCT02494167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (62% lower).

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which MultiTAA-specific T cells is the first listed.

NCT02494167 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02494167 about?

NCT02494167 is a clinical study titled "Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)". This research study uses special blood cells called multiple tumor-associated antigen (TAA)-specific T cells (a new experimental therapy) to treat patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) which has come back, or may come back, or has not gone away after standard t...

What is the current status of trial NCT02494167?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-02. Estimated completion is 2027-02.

What conditions does trial NCT02494167 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome.

What interventions are being tested in trial NCT02494167?

The interventions under investigation include: MultiTAA-specific T cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT02494167?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02494167 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02494167's enrollment target sits among peer trials

44 163rd of 306 higher than 142 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323945 · 44 participants · NA

    Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury

  • NCT03093909 · 44 participants · Phase 1

    Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

  • NCT03104491 · 44 participants · Phase 1

    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

  • NCT03781765 · 44 participants · Phase 4

    Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02494167, the US trial registry maintained by the National Library of Medicine. NCT02494167 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.